By: IPP Bureau
Last updated : November 11, 2025 10:38 am
Enabling a new era in minimally invasive obesity treatment across Europe
Nitinotes Surgical’s EndoZip automated suturing platform has received CE mark approval, paving the way for its commercial launch across Europe. EndoZip is designed to simplify and standardize endoscopic sleeve gastroplasty (ESG) — a minimally invasive weight-loss procedure that reduces stomach volume without external incisions.
As the first fully automated suturing platform for ESG, EndoZip aims to enhance procedural efficiency, shorten physician learning curves, and improve patient outcomes. By automating the historically manual suturing process, the platform allows for faster, more consistent, and precise endoscopic procedures.
“With EndoZip, we have the potential to dramatically expand patient access to a safe, durable, and minimally invasive obesity treatment while creating significant value for providers and healthcare systems,” said Lloyd Diamond, CEO of Nitinotes.
The company plans an initial rollout in select European centres of excellence, focusing on building clinical adoption and generating real-world data to support broader market expansion. In parallel, Nitinotes is preparing a pivotal Investigational Device Exemption (IDE) trial in the United States to support a future FDA submission.
Endoscopic sleeve gastroplasty is emerging as a compelling alternative for patients who have not achieved meaningful weight loss with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, but are reluctant to undergo invasive bariatric surgery like gastric bypass.
While GLP-1RAs have dominated recent obesity treatment discussions, studies continue to highlight ESG’s long-term value. Research published in JAMA suggests ESG offers superior cost-effectiveness and durability compared to pharmacologic treatments, with many patients regaining up to two-thirds of their lost weight within a year of stopping GLP-1 therapy.
As cost dynamics evolve—particularly following the recent agreements by Eli Lilly and Novo Nordisk with the US government to lower GLP-1RA prices—EndoZip’s CE mark positions Nitinotes at the forefront of next-generation, minimally invasive weight-loss solutions.